Clinicopathological indices to predict hepatocellular carcinoma molecular classification

Poh Seng Tan, Shigeki Nakagawa, Nicolas Goossens, Anu Venkatesh, Tiangui Huang, Stephen C. Ward, Xiaochen Sun, Won Min Song, Anna Koh, Claudia Canasto-Chibuque, Manjeet Deshmukh, Venugopalan Nair, Milind Mahajan, Bin Zhang, Maria Isabel Fiel, Masahiro Kobayashi, Hiromitsu Kumada, Yujin Hoshida

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background & Aims: Hepatocellular carcinoma (HCC) is the second most lethal cancer caused by lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification. Methods: Hepatocellular carcinoma classification defined in our previous transcriptome meta-analysis (S1, S2 and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumours (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were independently validated in 99 HCC tumours (validation set). Molecular deregulations associated with the histopathological features were determined by pathway analysis. Sample sizes for HCC clinical trials enriched with specific molecular subclasses were determined. Results: Hepatocellular carcinoma subclass-predictive indices were steatohepatitic (SH)-HCC variant and immune cell infiltrate for S1 subclass, macrotrabecular/compact pattern, lack of pseudoglandular pattern, and high serum alpha-foetoprotein (>400 ng/ml) for S2 subclass, and microtrabecular pattern, lack of SH-HCC and clear cell variants, and lower histological grade for S3 subclass. Macrotrabecular/compact pattern, a predictor of S2 subclass, was associated with the activation of therapeutically targetable oncogene YAP and stemness markers EPCAM/KRT19. BMP4 was associated with pseudoglandular pattern. Subclass-predictive indices-based patient enrichment reduced clinical trial sample sizes from 121, 184 and 53 to 30, 43 and 22 for S1, S2 and S3 subclass-targeting therapies respectively. Conclusions: Hepatocellular carcinoma molecular subclasses can be enriched by clinicopathological indices tightly associated with deregulation of therapeutically targetable molecular pathways.

Original languageEnglish (US)
Pages (from-to)108-118
Number of pages11
JournalLiver International
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Clinical Trials
Sample Size
Neoplasms
alpha-Fetoproteins
Gene Expression Profiling
Oncogenes
Meta-Analysis
Therapeutics

Keywords

  • Clinical diagnostic
  • Gene expression
  • Histopathology
  • Molecular subclass
  • Predictive index

ASJC Scopus subject areas

  • Hepatology

Cite this

Tan, P. S., Nakagawa, S., Goossens, N., Venkatesh, A., Huang, T., Ward, S. C., ... Hoshida, Y. (2016). Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver International, 36(1), 108-118. https://doi.org/10.1111/liv.12889

Clinicopathological indices to predict hepatocellular carcinoma molecular classification. / Tan, Poh Seng; Nakagawa, Shigeki; Goossens, Nicolas; Venkatesh, Anu; Huang, Tiangui; Ward, Stephen C.; Sun, Xiaochen; Song, Won Min; Koh, Anna; Canasto-Chibuque, Claudia; Deshmukh, Manjeet; Nair, Venugopalan; Mahajan, Milind; Zhang, Bin; Fiel, Maria Isabel; Kobayashi, Masahiro; Kumada, Hiromitsu; Hoshida, Yujin.

In: Liver International, Vol. 36, No. 1, 01.01.2016, p. 108-118.

Research output: Contribution to journalArticle

Tan, PS, Nakagawa, S, Goossens, N, Venkatesh, A, Huang, T, Ward, SC, Sun, X, Song, WM, Koh, A, Canasto-Chibuque, C, Deshmukh, M, Nair, V, Mahajan, M, Zhang, B, Fiel, MI, Kobayashi, M, Kumada, H & Hoshida, Y 2016, 'Clinicopathological indices to predict hepatocellular carcinoma molecular classification', Liver International, vol. 36, no. 1, pp. 108-118. https://doi.org/10.1111/liv.12889
Tan PS, Nakagawa S, Goossens N, Venkatesh A, Huang T, Ward SC et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver International. 2016 Jan 1;36(1):108-118. https://doi.org/10.1111/liv.12889
Tan, Poh Seng ; Nakagawa, Shigeki ; Goossens, Nicolas ; Venkatesh, Anu ; Huang, Tiangui ; Ward, Stephen C. ; Sun, Xiaochen ; Song, Won Min ; Koh, Anna ; Canasto-Chibuque, Claudia ; Deshmukh, Manjeet ; Nair, Venugopalan ; Mahajan, Milind ; Zhang, Bin ; Fiel, Maria Isabel ; Kobayashi, Masahiro ; Kumada, Hiromitsu ; Hoshida, Yujin. / Clinicopathological indices to predict hepatocellular carcinoma molecular classification. In: Liver International. 2016 ; Vol. 36, No. 1. pp. 108-118.
@article{a6c893df446947fab7baadc73f173847,
title = "Clinicopathological indices to predict hepatocellular carcinoma molecular classification",
abstract = "Background & Aims: Hepatocellular carcinoma (HCC) is the second most lethal cancer caused by lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification. Methods: Hepatocellular carcinoma classification defined in our previous transcriptome meta-analysis (S1, S2 and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumours (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were independently validated in 99 HCC tumours (validation set). Molecular deregulations associated with the histopathological features were determined by pathway analysis. Sample sizes for HCC clinical trials enriched with specific molecular subclasses were determined. Results: Hepatocellular carcinoma subclass-predictive indices were steatohepatitic (SH)-HCC variant and immune cell infiltrate for S1 subclass, macrotrabecular/compact pattern, lack of pseudoglandular pattern, and high serum alpha-foetoprotein (>400 ng/ml) for S2 subclass, and microtrabecular pattern, lack of SH-HCC and clear cell variants, and lower histological grade for S3 subclass. Macrotrabecular/compact pattern, a predictor of S2 subclass, was associated with the activation of therapeutically targetable oncogene YAP and stemness markers EPCAM/KRT19. BMP4 was associated with pseudoglandular pattern. Subclass-predictive indices-based patient enrichment reduced clinical trial sample sizes from 121, 184 and 53 to 30, 43 and 22 for S1, S2 and S3 subclass-targeting therapies respectively. Conclusions: Hepatocellular carcinoma molecular subclasses can be enriched by clinicopathological indices tightly associated with deregulation of therapeutically targetable molecular pathways.",
keywords = "Clinical diagnostic, Gene expression, Histopathology, Molecular subclass, Predictive index",
author = "Tan, {Poh Seng} and Shigeki Nakagawa and Nicolas Goossens and Anu Venkatesh and Tiangui Huang and Ward, {Stephen C.} and Xiaochen Sun and Song, {Won Min} and Anna Koh and Claudia Canasto-Chibuque and Manjeet Deshmukh and Venugopalan Nair and Milind Mahajan and Bin Zhang and Fiel, {Maria Isabel} and Masahiro Kobayashi and Hiromitsu Kumada and Yujin Hoshida",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/liv.12889",
language = "English (US)",
volume = "36",
pages = "108--118",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinicopathological indices to predict hepatocellular carcinoma molecular classification

AU - Tan, Poh Seng

AU - Nakagawa, Shigeki

AU - Goossens, Nicolas

AU - Venkatesh, Anu

AU - Huang, Tiangui

AU - Ward, Stephen C.

AU - Sun, Xiaochen

AU - Song, Won Min

AU - Koh, Anna

AU - Canasto-Chibuque, Claudia

AU - Deshmukh, Manjeet

AU - Nair, Venugopalan

AU - Mahajan, Milind

AU - Zhang, Bin

AU - Fiel, Maria Isabel

AU - Kobayashi, Masahiro

AU - Kumada, Hiromitsu

AU - Hoshida, Yujin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background & Aims: Hepatocellular carcinoma (HCC) is the second most lethal cancer caused by lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification. Methods: Hepatocellular carcinoma classification defined in our previous transcriptome meta-analysis (S1, S2 and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumours (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were independently validated in 99 HCC tumours (validation set). Molecular deregulations associated with the histopathological features were determined by pathway analysis. Sample sizes for HCC clinical trials enriched with specific molecular subclasses were determined. Results: Hepatocellular carcinoma subclass-predictive indices were steatohepatitic (SH)-HCC variant and immune cell infiltrate for S1 subclass, macrotrabecular/compact pattern, lack of pseudoglandular pattern, and high serum alpha-foetoprotein (>400 ng/ml) for S2 subclass, and microtrabecular pattern, lack of SH-HCC and clear cell variants, and lower histological grade for S3 subclass. Macrotrabecular/compact pattern, a predictor of S2 subclass, was associated with the activation of therapeutically targetable oncogene YAP and stemness markers EPCAM/KRT19. BMP4 was associated with pseudoglandular pattern. Subclass-predictive indices-based patient enrichment reduced clinical trial sample sizes from 121, 184 and 53 to 30, 43 and 22 for S1, S2 and S3 subclass-targeting therapies respectively. Conclusions: Hepatocellular carcinoma molecular subclasses can be enriched by clinicopathological indices tightly associated with deregulation of therapeutically targetable molecular pathways.

AB - Background & Aims: Hepatocellular carcinoma (HCC) is the second most lethal cancer caused by lack of effective therapies. Although promising, HCC molecular classification, which enriches potential responders to specific therapies, has not yet been assessed in clinical trials of anti-HCC drugs. We aimed to overcome these challenges by developing clinicopathological surrogate indices of HCC molecular classification. Methods: Hepatocellular carcinoma classification defined in our previous transcriptome meta-analysis (S1, S2 and S3 subclasses) was implemented in an FDA-approved diagnostic platform (Elements assay, NanoString). Ninety-six HCC tumours (training set) were assayed to develop molecular subclass-predictive indices based on clinicopathological features, which were independently validated in 99 HCC tumours (validation set). Molecular deregulations associated with the histopathological features were determined by pathway analysis. Sample sizes for HCC clinical trials enriched with specific molecular subclasses were determined. Results: Hepatocellular carcinoma subclass-predictive indices were steatohepatitic (SH)-HCC variant and immune cell infiltrate for S1 subclass, macrotrabecular/compact pattern, lack of pseudoglandular pattern, and high serum alpha-foetoprotein (>400 ng/ml) for S2 subclass, and microtrabecular pattern, lack of SH-HCC and clear cell variants, and lower histological grade for S3 subclass. Macrotrabecular/compact pattern, a predictor of S2 subclass, was associated with the activation of therapeutically targetable oncogene YAP and stemness markers EPCAM/KRT19. BMP4 was associated with pseudoglandular pattern. Subclass-predictive indices-based patient enrichment reduced clinical trial sample sizes from 121, 184 and 53 to 30, 43 and 22 for S1, S2 and S3 subclass-targeting therapies respectively. Conclusions: Hepatocellular carcinoma molecular subclasses can be enriched by clinicopathological indices tightly associated with deregulation of therapeutically targetable molecular pathways.

KW - Clinical diagnostic

KW - Gene expression

KW - Histopathology

KW - Molecular subclass

KW - Predictive index

UR - http://www.scopus.com/inward/record.url?scp=84933557723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933557723&partnerID=8YFLogxK

U2 - 10.1111/liv.12889

DO - 10.1111/liv.12889

M3 - Article

C2 - 26058462

AN - SCOPUS:84933557723

VL - 36

SP - 108

EP - 118

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 1

ER -